Cardiol Therapeutics Inc. (CRDL) Fair Value 2026

CRDL · Drug Manufacturers - Specialty & Generic ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.3 /10

32 fundamental signals · 0 models active

Value Trap Risk

LOW (28/100)

Quick Summary — As of 2026-08-28, Cardiol Therapeutics Inc. (CRDL) trades at $1.94. QOC: 6.3/10. Value Trap Risk: 28/100 (LOW). 0/13 models active.

Key Facts

Ticker
CRDL
Price
$1.94
Quality Score
6.3/10
Value Trap Risk
28/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Limited model coverage (0/13) may reduce confidence

What Fair Value Does Each Model Give CRDL?

0 Intrinsic Value Models vs. Current Price ($1.94)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is Cardiol Therapeutics Inc. (CRDL) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Cardiol Therapeutics Inc. currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About CRDL?

0 of 13 models are currently active for CRDL. See which stocks rank higher →

How Does CRDL Rank in Drug Manufacturers - Specialty & Generic?

Among 112 Drug Manufacturers - Specialty & Generic stocks, CRDL ranks #43 by Quality of Company score. CirclFi's QOC score of 6.3/10 evaluates 32 fundamental signals. A score of 6.3 indicates above-average quality.

See all Most Undervalued Drug Manufacturers - Specialty & Generic Stocks →

As a biopharma enterprise, Cardiol Therapeutics Inc. operates in a sector where revenue per drug is a critical driver of valuation. Investors evaluating CRDL should weigh these sector-specific dynamics alongside our model-derived fair values.

Is CRDL a Value Trap?

CirclFi's Value Trap algorithm assigns CRDL a score of 28/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for Cardiol Therapeutics Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Cardiol Therapeutics Inc.'s fundamental quality profile registers 6.3/10. This respectable score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every CRDL valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Cardiol Therapeutics Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Drug Manufacturers - Specialty & Generic Stocks Should You Also Analyze?

11 related Drug Manufacturers - Specialty & Generic stocks with 13-model coverage

ALVOAlvotechQOC 6.3CPIXCumberland Pharmaceuticals Inc.QOC 6.3SNOASonoma Pharmaceuticals, Inc.QOC 6.3ZYBTZhengye Biotechnology Holding LimitedQOC 6.2ACBAurora Cannabis Inc.QOC 6.5TXMDTherapeuticsMD, Inc.QOC 6.2YCBDcbdMD, Inc.QOC 5.3PTPIPetros Pharmaceuticals, Inc.QOC 4.1SIGASIGA Technologies, Inc.QOC 8.4UTHRUnited Therapeutics CorporationQOC 9.6AMPHAmphastar Pharmaceuticals, Inc.QOC 9.4

Read investment analysis: ALVO · CPIX · SNOA · ZYBT · ACB · TXMD · YCBD · PTPI · SIGA · UTHR · AMPH

Which Other Stocks Have a Similar Quality Score to CRDL?

7 companies across all industries closest to CRDL’s Quality of Company score of 6.3/10.

THTarget Hospitality Corp.QOC 6.3BDSXBiodesix, Inc.QOC 6.3CVEOCiveo CorporationQOC 6.3PHATPhathom Pharmaceuticals, Inc.QOC 6.3FLUTFlutter Entertainment plcQOC 6.3MRMMEDIROM Healthcare Technologies Inc.QOC 6.3NVDANVIDIA CorporationQOC 10.0

Read investment analysis: TH · BDSX · CVEO · PHAT · FLUT · MRM · NVDA

Where Does CRDL Sit in CirclFi's Drug Manufacturers - Specialty & Generic Rankings?

CRDL is ranked against every other Drug Manufacturers - Specialty & Generic stock CirclFi covers in each of these screens.

See all Drug Manufacturers - Specialty & Generic stocks ranked →

What Else Do Investors Ask About Cardiol Therapeutics Inc.’s Valuation?

What is Cardiol Therapeutics Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Cardiol Therapeutics Inc. (CRDL). The Quality of Company score is 6.3/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is CRDL overvalued or undervalued right now?

At $1.94, 0 of 0 active models suggest CRDL may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Cardiol Therapeutics Inc.'s business model in Drug Manufacturers - Specialty & Generic.

What does a Quality of Company score of 6.3 mean for CRDL?

Cardiol Therapeutics Inc.'s QOC of 6.3/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on CRDL?

CirclFi analyzes CRDL with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is CRDL a value trap in 2026?

Cardiol Therapeutics Inc.'s Value Trap score is 28/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Cardiol Therapeutics Inc. (CRDL) a Quality of Company score of 6.3/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/CRDL/ · Methodology
Primary sources for this CRDL valuation
  • Financial statements: Cardiol Therapeutics Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001702123) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for CRDL as of ; valuations recomputed .